[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"IRCCS SYNLAB SDN\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,61],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100583608","observational-study-analysing-the-transcriptome-and-mutational-status-of-thyroid-carcinomas-of-follicular-origin-with-different-degrees-of-malignancy-100583608",false,"NCT06878534","Observational Study Analysing the Transcriptome and Mutational Status of Thyroid Carcinomas of Follicular Origin with Different Degrees of Malignancy","TRAMT","Inclusion Criteria:\n\n* Patients of either sex aged \\> 18 years with thyroid cancer of follicular origin.\n\nExclusion Criteria:\n\n* Patients who do not fit the inclusion criteria.",true,"ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","OBSERVATIONAL","Thyroid cancer (TC) is the most common endocrine malignancy, with well-differentiated thyroid carcinomas (DTCs)-papillary (PTC) and follicular (FTC)-comprising the majority of cases. While DTCs generally have favorable prognoses, a subset progresses to poorly differentiated or anaplastic thyroid carcinoma (ATC), which is highly aggressive. Tumor classification is based on histopathology, invasiveness, and molecular characteristics, with new entities like thyroid tumors of uncertain malignant potential (TT-UMP) and non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) refining diagnostic criteria.\n\nCurrent standard treatments include surgical resection, radioactive iodine therapy, and thyroid hormone replacement. However, some patients develop radioiodine-refractory disease with an increased risk of recurrence and progression. Molecular alterations in the MAPK and PI3K pathways play critical roles in thyroid tumorigenesis, influencing therapeutic response and prognosis. Identifying novel biomarkers for early detection and risk stratification is crucial. Emerging evidence highlights the role of microRNAs (miRNAs) in thyroid cancer progression, functioning as oncogenes or tumor suppressors.\n\nThis retrospective case-control study aims to identify novel molecular markers linked to thyroid cancer aggressiveness. Archived formalin-fixed paraffin-embedded (FFPE) tissue and blood samples will be analyzed from patients with varying degrees of PTC and FTC invasiveness. Control samples will be histologically normal thyroid tissue from the same patients.\n\nNext Generation Sequencing (NGS), including RNA-seq and miRNA-seq, will be employed to detect differentially expressed RNA molecules. Validation will be performed using Real-Time PCR in an independent cohort. High-throughput genomic sequencing (Illumina TruSight Oncology 500) will assess mutations, copy number variations, and tumor mutation burden to correlate genetic alterations with malignancy. Variants will be prioritized based on frequency differences in tumor vs. non-tumor populations and functional relevance.\n\nThe study will enroll patients with follicular cell-derived thyroid carcinoma. A power analysis indicates that 80 subjects provide \\>80% statistical power for biomarker identification. Descriptive statistics, parametric\u002Fnon-parametric tests, and machine learning approaches will analyze transcriptomic and genomic data. Receiver operating characteristic (ROC) curves will assess diagnostic biomarker accuracy, while logistic regression will model associations between molecular alterations and disease severity.\n\nThis study aims to uncover molecular mechanisms driving thyroid cancer progression and identify biomarkers for improved risk stratification, early diagnosis, and potential therapeutic targeting. Findings may enhance personalized treatment approaches in thyroid oncology.",[25],"Thyroid Cancer",[27],"Thyroid Cancer, miRNA, non coding RNA","RECRUITING","2025-03-12",{"date":31,"type":32},"2025-03-17","ACTUAL",{"date":34,"type":32},"2023-03-13",{"date":36,"type":21},"2027-03-31",{"name":38,"class":39},"IRCCS SYNLAB SDN","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":40},"100582921","evaluation-of-adherence-to-the-mediterranean-diet-in-patients-with-recurrent-renal-stones-and-disease-osteometabolic-100582921","NCT06869603","Evaluation of Adherence to the Mediterranean Diet in Patients with Recurrent Renal Stones and Disease Osteometabolic","Inclusion Criteria:\n\n* Patients with idiopathic relapsing nephrolithiasis with evidence instrumental of bilateral renal stones or emission of more than one stone in the past 5 years\n\nExclusion Criteria:\n\n* Patients who had albumin-corrected plasma calcium levels \\> 11.0 mg\u002Fdl at the time of the first determination of serum levels of 25 OH vitamin D;\n* Patients who had glomerular filtration rate \\\u003C 60 mL\u002Fmin\u002F1.73 m2;\n* Patients who had positive personal history of chronic granulomatous disease;\n* pregnancy patients;\n* Positive personal history for morphological abnormalities of the excretory system;\n* incomplete data collection.",{"count":48,"type":21},50,"The aim of this research protocol is to evaluate the adherence to the Mediterranean diet in patients suffering from recurrent kidney stones and osteometabolic diseases. Results of the study will allow to assess the dietary habits of patients with the above diseases. Given the universal prevalence of nephrolithiasis and osteometabolic diseases, the knowledge of these data appears crucial for the proper management of the dietary approach to prophylaxis secondar",[51,52],"Renal Stones","Osteometabolic Disease","2025-03-10",{"date":55,"type":32},"2025-03-11",{"date":57,"type":32},"2023-12-07",{"date":59,"type":21},"2026-12",{"name":38,"class":39},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":40},"100542004","potential-role-of-sirtuins-as-epigenetic-biomarkers-of-the-patient-with-atherosclerosis-or-calcific-aortic-stenosis-100542004","NCT06337227","Potential Role of Sirtuins As Epigenetic Biomarkers of the Patient with Atherosclerosis or Calcific Aortic Stenosis","Potential Role of Sirtuins As Epigenetic Biomarkers for the Clinical Management of the Patient with Atherosclerosis or Calcific Aortic Stenosis","Inclusion Criteria:\n\n* Patients with atherosclerosis or calcific aortic stenosis with and without diabetes older than 18 years of either sex;\n* Patients without atherosclerosis undergoing surgical procedure for endocarditis;\n* Patients who will have signed informed consent\n\nExclusion Criteria:\n\n* Patients for whom biological material cannot be recovered for study purposes;\n* Patients who refuse to participate in the study",{"count":5,"type":21},"The project aims to shed light on the role of Sirtuins, enzymes belonging to the third class of histone deacetylases (class III) involved in epigenetic modifications (deacetylation), focusing mainly on Sirtuin 6 (SIRT6), as a regulator of atherosclerosis and severe aortic valve stenosis through molecular-based and epigenetic studies in human VSMC cells.",[71],"Atherosclerosis and Calcific Aortic Stenosis with and Without Diabetes","2025-03-07",{"date":55,"type":32},{"date":75,"type":32},"2023-10-19",{"date":77,"type":21},"2026-10",{"name":38,"class":39},""]